- Home
- NIKI vs ENVB Comparison
NIKI vs ENVB Comparison
Compare NIKI & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$5.96
HOLD
Current Price
$1.46
Company Overview
Basic Information| Metric | NIKI | ENVB |
|---|---|---|
| Founded | N/A | 1994 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 8.1M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NIKI | ENVB |
|---|---|---|
| Price | $5.96 | $1.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 237.6K | 99.0K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.91 | $0.56 |
| 52 Week High | $10.39 | $13.25 |
Technical Indicators
Market Signals| Indicator | NIKI | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 34.07 | 51.87 |
| Support Level | N/A | $1.17 |
| Resistance Level | $9.43 | $1.53 |
| Average True Range (ATR) | 0.77 | 0.09 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 9.02 | 79.99 |
Price Performance
Historical Comparison NIKI
ENVB
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.